Stock THER THERALINK TECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Theralink Technologies, Inc.

Equities

THER

US88339Q1094

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 08:12:37 20/05/2024 pm IST 		5-day change 1st Jan Change
0.0007 USD 0.00% Intraday chart for Theralink Technologies, Inc. 0.00% -53.33%
06/05 Theralink Technologies, Inc. cancelled the acquisition of IMAC Holdings, Inc. in a reverse merger transaction. CI
20/02 Theralink Technologies, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI

Valuation

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Capitalization 1 5.384 0.1723 0.4404 256.2 21.53 5.536
Enterprise Value (EV) 1 7.672 4.001 -0.9578 256.4 25.51 24.3
P/E ratio -6.57 x -0.02 x -5.15 x -40.5 x -1.59 x -0.18 x
Yield - - - - - -
Capitalization / Revenue - - 24,30,031 x 50,67,36,960 x 3,79,11,709 x 91,23,905 x
EV / Revenue - - -52,85,054 x 50,70,41,226 x 4,49,15,754 x 4,00,45,900 x
EV / EBITDA -4.32 x -2.27 x 0.29 x -47.6 x -2.23 x -2.85 x
EV / FCF -0.88 x 0.64 x 0.34 x -173 x -11.8 x 1.23 x
FCF Yield -114% 156% 291% -0.58% -8.48% 81.1%
Price to Book -0.77 x -0.02 x -5,250 x -51.8 x -3.17 x -0.15 x
Nbr of stocks (in thousands) 326 467 1,398 51,24,165 61,51,500 61,51,500
Reference price 2 16.50 0.3688 0.3150 0.0500 0.003500 0.000900
Announcement Date 01/04/19 25/03/20 27/09/21 13/01/22 29/12/22 05/01/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Net sales - - 0.1812 0.5056 0.5679 0.6068
EBITDA 1 -1.776 -1.766 -3.259 -5.38 -11.45 -8.532
EBIT 1 -1.778 -1.769 -3.357 -5.566 -11.64 -8.741
Operating Margin - - -1,852.24% -1,100.86% -2,049.64% -1,440.47%
Earnings before Tax (EBT) 1 6.468 -9.402 -3.17 -5.472 -12.74 -30.91
Net income 1 6.468 -9.402 -3.17 -5.472 -12.74 -30.91
Net margin - - -1,749.32% -1,082.2% -2,243.68% -5,093.56%
EPS 2 -2.510 -19.00 -0.0611 -0.001236 -0.002207 -0.005030
Free Cash Flow 1 -8.714 6.256 -2.788 -1.482 -2.162 19.71
FCF margin - - -1,538.27% -293.12% -380.67% 3,248.94%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 01/04/19 25/03/20 27/09/21 13/01/22 29/12/22 05/01/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Net Debt 1 2.29 3.83 - 0.15 3.98 18.8
Net Cash position 1 - - 1.4 - - -
Leverage (Debt/EBITDA) -1.289 x -2.168 x - -0.0286 x -0.3474 x -2.199 x
Free Cash Flow 1 -8.71 6.26 -2.79 -1.48 -2.16 19.7
ROE (net income / shareholders' equity) -57.9% 80.1% -598% 4,326% 443% 147%
ROA (Net income/ Total Assets) -876% -689% -97.6% -144% -343% -201%
Assets 1 -0.7385 1.364 3.248 3.802 3.711 15.41
Book Value Per Share 2 -21.40 -18.60 -0 -0 -0 -0.0100
Cash Flow per Share 2 0 0.0300 0 0 0 0
Capex - 0.04 0.53 0.14 0.13 0.16
Capex / Sales - - 293.3% 26.84% 23.17% 26.93%
Announcement Date 01/04/19 27/09/21 27/09/21 13/01/22 29/12/22 05/01/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
THERALINK TECHNOLOGIES, INC. Stock Theralink Technologies, Inc.
-53.33% 43.06L
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.83% 12TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.80% 10TCr
BIONTECH SE Stock BioNTech SE
-10.84% 2.27TCr
ARGENX SE Stock argenx SE
+1.69% 2.18TCr
GENMAB A/S Stock Genmab A/S
-10.81% 1.82TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.92% 1.65TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.11% 1.6TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.62% 1.41TCr
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+17.53% 1.07TCr
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. THER Stock
  4. Financials Theralink Technologies, Inc.